Abstract
SummaryThe use of antiangiogenic agents in cancer therapy has become an attractive target in oncological research. However, concerning the uro-oncological field, current guidelines only recommend the use of antiangiogenic agents in metastatic renal cell cancer. Yet in recent years, several approaches for sequential treatment with angiogenesis inhibitors in other urogenital malignancies apart from renal cell cancer are ongoing. Thus, the present review article aims to provide an overview about clinical studies with antiangiogenic agents in prostate-, bladder-, testicular-, as well as penile cancer patients. For this, a literature search was conducted using Medline; moreover we performed a systematic review of data presented at this year’s important urooncological meetings. Preliminary data revealed that there are several promising studies ongoing in prostate-, bladder-, testicular-, as well as penile cancer; however, larger studies should be conducted to optimize the use of antiangiogenic agents in clinical practice.
Highlights
Tumor angiogenesis plays an important role in cancer growth and metastatic dissemination
Most of the antiangiogenic agents used in metastatic renal cell cancer (mRCC) are inhibitors of the vascular endothelial growth factor (VEGF) pathway and their use has become an integral part of therapy for patients with mRCC recommended as first line-treatment in the Europan Urology Association (EAU) guidelines [3]
Compared to the androgen deprivation therapy (ADT)-alone arm, patients treated with ADT + bevacizumab had a significant improvement in relapse-free survival (RFS) (13.3 months for ADT + bevacizumab vs 10.2 months ADT alone, p = 0.002)
Summary
Received: 30 August 2017 / Accepted: 7 November 2017 / Published online: 4 December 2017. Summary The use of antiangiogenic agents in cancer therapy has become an attractive target in oncological research. Concerning the uro-oncological field, current guidelines only recommend the use of antiangiogenic agents in metastatic renal cell cancer. Several approaches for sequential treatment with angiogenesis inhibitors in other urogenital malignancies apart from renal cell cancer are ongoing. The present review article aims to provide an overview about clinical studies with antiangiogenic agents in prostate-, bladder-, testicular-, as well as penile cancer patients. Preliminary data revealed that there are several promising studies ongoing in prostate-, bladder-, testicular-, as well as penile cancer; larger studies should be conducted to optimize the use of antiangiogenic agents in clinical practice. Keywords Prostate cancer · Testicular cancer · Penile cancer · Urothelial cancer · Antiangiogenic therapeutics
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
